Search research articles
Contact Us
Filters
Showing results (391-400 of 491) with videos related to
Page
of 50
Sort By:
Dermatology and Therapy
|
December 12, 2022
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)
Paolo Gisondi, Alice B Gottlieb, Boni Elewski, et al.
Dermatology and Therapy
|
July 7, 2022
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
April Armstrong, Kyle Fahrbach, Craig Leonardi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 2, 2017
Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis
Hema N Viswanathan, Alex Mutebi, Cassandra E Milmont, et al.
Oncotarget
|
June 15, 2018
The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians
Katharina C Kähler, Christine Blome, Andrea Forschner, et al.
JAMA Dermatology
|
October 14, 2020
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials
Matthias Augustin, Jo Lambert, Carla Zema, et al.
Acta Dermato-Venereologica
|
July 15, 2021
Patient-Reported Outcome Measures in Dermatology: A Systematic Review
Rachael L Pattinson, Nirohshah Trialonis-Suthakharan, Sunnia Gupta, et al.
Dermatology and Therapy
|
June 5, 2026
Association Between Bimekizumab's Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II
Steven Daveluy, Alice Bendix Gottlieb, Matthias Augustin, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
May 23, 2024
SARS-CoV-2 infection among psoriasis patients in Germany: Data from the German registries PsoBest and CoronaBest
María José Valencia López, Anna Meineke, Brigitte Stephan, et al.
JAMA Dermatology
|
February 18, 2026
Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension
Matthias Augustin, Steven R Feldman, Richard B Warren, et al.
Journal of the American Academy of Dermatology
|
October 26, 2017
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
Lluís Puig, Matthias Augustin, Andrew Blauvelt, et al.
Page
of 50
Search research articles
Search
Showing results (391-400 of 491) with videos related to
Sort By:
Page
of 50
Dermatology and Therapy
|
December 12, 2022
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)
Paolo Gisondi, Alice B Gottlieb, Boni Elewski, et al.
Dermatology and Therapy
|
July 7, 2022
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
April Armstrong, Kyle Fahrbach, Craig Leonardi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 2, 2017
Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis
Hema N Viswanathan, Alex Mutebi, Cassandra E Milmont, et al.
Oncotarget
|
June 15, 2018
The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians
Katharina C Kähler, Christine Blome, Andrea Forschner, et al.
JAMA Dermatology
|
October 14, 2020
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials
Matthias Augustin, Jo Lambert, Carla Zema, et al.
Acta Dermato-Venereologica
|
July 15, 2021
Patient-Reported Outcome Measures in Dermatology: A Systematic Review
Rachael L Pattinson, Nirohshah Trialonis-Suthakharan, Sunnia Gupta, et al.
Dermatology and Therapy
|
June 5, 2026
Association Between Bimekizumab's Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II
Steven Daveluy, Alice Bendix Gottlieb, Matthias Augustin, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
May 23, 2024
SARS-CoV-2 infection among psoriasis patients in Germany: Data from the German registries PsoBest and CoronaBest
María José Valencia López, Anna Meineke, Brigitte Stephan, et al.
JAMA Dermatology
|
February 18, 2026
Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension
Matthias Augustin, Steven R Feldman, Richard B Warren, et al.
Journal of the American Academy of Dermatology
|
October 26, 2017
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
Lluís Puig, Matthias Augustin, Andrew Blauvelt, et al.
Page
of 50